Phase 1/2 Neurology Deal Benchmarks

Median Upfront

$223M

Range: $101M - $351M

Total Deal Value

$2.3B

Range: $1.3B - $3.4B

Royalty Rate

9.9% - 17.3%

Tiered up to 21.3%

Dev Milestones

$885M

Range: $496M - $1.3B

Model Your Deal

Market Analysis

Phase 1/2 neurology licensing deals carry a median total deal value of $2.3B, with upfront payments ranging from $101M to $351M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 10% to upfront and 90% to milestones.

The neurology landscape at the phase 1/2 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $885M, regulatory milestones contribute $695M, and commercial milestones reach $527M. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 1/2 neurology deals range from 9.9% to 17.3% at the base tier, with high-tier escalation to 21.3%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1/2 neurology deals?

Phase 1/2 neurology deals average $223M in upfront payments, ranging from $101M to $351M. The upfront allocation of 10% of total deal value reflects the clinical stage risk profile.

How are phase 1/2 neurology deal milestones structured?

Milestones account for approximately 90% of total deal value. Development milestones ($885M) represent the largest component, followed by commercial milestones ($527M) and regulatory milestones ($695M).

What royalty rates are typical for phase 1/2 neurology licensing?

Base royalty rates range from 9.9% to 17.3%, with tiered escalation to 13.9%-21.3% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 1/2 Neurology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Neurology Deals

Phase 1 Neurology Deals

Phase 1/2 Oncology Deals

Phase 1/2 Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?